medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 3

<< Back Next >>

Med Int Mex 2023; 39 (3)

Update on multidrug-resistant tuberculosis treatment

Gamboa-Hernández NG, Reyes-Ruvalcaba D, Ángel-Chávez LI, Quiroz-Herrera FY, González-Salazar F

Language: Spanish
References: 50
Page: 482-494
PDF size: 260.99 Kb.


ABSTRACT

Despite technological advances in the world, antimicrobial resistance against Mycobacterium tuberculosis represents a great threat to public health. Worldwide, 20% of tuberculosis cases are multidrug-resistant, and the number of patients continues to increase day after day. The successful treatment of tuberculosis has become a great challenge for global health according to the World Health Organization. This review aims to give a general overview of tuberculosis, including its history, generalities, epidemiology, and treatment, and to give a broader review of new treatment proposals, reviewing their sensitivity, specificity, and reduced numbers of side effects. PubMed, Google Scholar, Elsevier, and EBSCOhost were used to obtain the main articles describing the research conducted on new drugs to treat multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. The clinical trials for the new drugs used to treat extensively drug-resistant tuberculosis demonstrated good therapeutic regimens and compared the new drugs to identify which of them had more efficacy and less toxicity. The new drugs developed to treat extensively drugresistant tuberculosis that were effective in 85%-90% of patients were bedaquiline, pretomanid, and linezolid.


REFERENCES

  1. Organización Mundial de la Salud. Global Tuberculosisreport. Geneva: World Health Prganization; 2019.

  2. Nahid P, Mase S, Battista G, Sotgiu G, et al. Treatment ofdrug-resistant tuberculosis. American Thoracic SocietyDocuments 2019; 200: e93-e142. https://doi.org/10.1164/rccm.201909-1874ST.

  3. Paneque E, Rojas L, Pérez M. La tuberculosis a través de laHistoria: un enemigo de la humanidad. Revista Habanerade Ciencias Médicas 2018; 17 (3): 353-363.

  4. Cruz A, Armas L, Plascencia A, Plascencia A. Desde lasprimeras nociones sobre la tuberculosis hasta la estrategia“fin de la tuberculosis”: desafíos sociales para la infanciaen México. Revista Cubana de Medicina Tropical 2017;69 (2): 1-15.

  5. González J. Microbiología de la tuberculosis. Seminariosde la Fundación Española de Reumatología 2014; 15 (1):25-33. https://doi.org/10.1016/j.semreu.2014.01.001.

  6. Flores M, Villalpando A. Fármacos en Evaluación Clínicapara el tratamiento de tuberculosis. Salud Jalisco 2018;2 (1): 42-51.

  7. Arango M. Historia natural de la tuberculosis. Fisiopatogeniade la infección y la enfermedad en el niño. NeumologíaPediátrica 2015; 10: 155-159.

  8. Pai M, Behr MA, Dowdy D, Dheda K, et al., Tuberculosis.Nat Rev Dis Primers. 2016; 2: 16076. doi: 10.1038/nrdp.2016.76.

  9. Fajardo G, Reyes O, Varela D, Medina K. Tuberculosis pulmonary métodos diagnósticos laboratoriales actuales. FacCienc Med 2018; 15: 35-44.

  10. Delgadillo J, Padilha C, Rodríguez K. Los pros y contras delos métodos de diagnóstico microbiológico de tuberculosis.Universidad Nuestra Señora de la Paz 2018; 1: 1-10.

  11. Navarro A, Marco S, Fernandez P, Moreno M, GomilaB, Ibañez M. Modelo predictivo clínico-radiológico paradiagnosticar tuberculosis pulmonar activa. Rev Chil Radiol2019; 25 (2): 47-49.

  12. Viñuelas-Bayón J, Vitoria MA, Samper S. Rapid diagnosisof tuberculosis. Detection of drug resistance mechanisms.Enferm Infecc Microbiol Clin 2017; 35 (8): 520-528. doi:10.1016/j.eimc.2017.01.015.

  13. Sardiñas M, García G, Rosarys Martínez M, Díaz R,Mederos LM. Importancia del control de la calidad dela baciloscopia en los laboratorios de diagnóstico de tuberculosis[Importance of quality control of baciloscopyin laboratories that perform diagnosis of tuberculosis].Rev Chilena Infectol 2016; 33 (3): 282-286. doi: 10.4067/S0716-10182016000300005.

  14. Arias F, Herrera T. Nuevos métodos para el diagnósticode la tuberculosis. Rev Chil Enferm Respir 2016; 32(4): 254-259. DOI: http://dx.doi.org/10.4067/S0717-73482016000400007.

  15. Bansal R, Sharma D, Singh R. Tuberculosis and itstreatment: An overview. Mini Rev Med Chem 2018; 18(1): 58-71. DOI: 10.2174/1389557516666160823160010.

  16. Caminero J. Actualización en el diagnóstico y tratamientode la tuberculosis pulmonar. Revista Clínica Española2016; 216 (2): 76-84. DOI: https://doi.org/10.1016/j.rce.2015.09.005.

  17. Rabahi MF, Silva Júnior JLRD, Ferreira ACG, Tannus-Silva DGS, Conde MB. Tuberculosis treatment. J BrasPneumol 2017; 43: 472-486. DOI: 10.1590/S1806-37562016000000388.

  18. Suárez I, Fünger SM, Kröger S, Rademacher J, FätkenheuerG, Rybniker J. The diagnosis and treatment of tuberculosis.Dtsch Arztebl Int 2019; 116 (43): 729-735. DOI: 10.3238/arztebl.2019.0729.

  19. Seaworth BJ, Griffith DE. Therapy of multidrug-resistantand extensively drug-resistant tuberculosis. MicrobiolSpectr 2017; 5 (2). DOI: 10.1128/microbiolspec.TNMI7-0042-2017.

  20. Block M, Blanchard DL. Aminoglycosides. 2021 Jul 23.In: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2022.

  21. Caminero JA, Cayla JA, García-García JM, García-Pérez FJ,Palacios JJ, Ruiz-Manzano J. Diagnosis and treatment ofdrug-resistant tuberculosis. Arch Bronconeumol 2017; 53(9): 501-509. DOI: 10.1016/j.arbres.2017.02.006.

  22. Yılmaz FF, Eraç B, Ermertcan Ş, Çavuşoğlu C, Biçmen C,Aktoğu Özkan S, Hoşgör Limoncu M. In vitro effects ofciprofloxacin, levofloxacin and moxifloxacin on Mycobacteriumtuberculosis isolates. Tuberk Toraks 2018; 66 (1):32-36. DOI: 10.5578/tt.58677.

  23. Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, etal. Levofloxacin pharmacokinetics/pharmacodynamics,dosing, susceptibility breakpoints, and artificial intelligencein the treatment of multidrug-resistant tuberculosis. ClinInfect Dis 2018; 67 (suppl. 3): S293-S302. DOI: 10.1093/cid/ciy611.

  24. AlMatar M, AlMandeal H, Var I, Kayar B, Köksal F. New drugsfor the treatment of Mycobacterium tuberculosis infection.Biomed Pharmacother 2017; 91: 546-558. DOI: 10.1016/j.biopha.2017.04.105.

  25. Vasava MS, Nair SG, Rathwa SK, Patel DB, Patel HD. Developmentof new drug-regimens against multidrug-resistanttuberculosis. Indian J Tuberc 2019; 66 (1): 12-19. DOI:10.1016/j.ijtb.2018.07.004.

  26. Keam SJ. Pretomanid: First Approval. Drugs 2019; 79 (16):1797-1803. DOI: 10.1007/s40265-019-01207-9.

  27. Wallis RS, Maeurer M, Mwaba P, Chakaya J, RustomjeeR, Migliori GB, Marais B, Schito M, Churchyard G, SwaminathanS, Hoelscher M, Zumla A. Tuberculosis--advancesin development of new drugs, treatment regimens, hostdirectedtherapies, and biomarkers. Lancet Infect Dis 2016;16 (4): e34-46. DOI: 10.1016/S1473-3099(16)00070-0.

  28. Mohammad A. Newly developed drugs invented to treattuberculosis in clinical trial. Journal of Chinese PharmaceuticalSciences 2017; 26 (1): 1-22. DOI: 10.5246/jcps.2017.01.001.

  29. Shah I, Poojari V, Meshram H. Multi-drug resistant andextensively-drug resistant tuberculosis. Indian J Pediatr2020; 87 (10): 833-839. DOI: 10.1007/s12098-020-03230-1.

  30. Ignatius EH, Dooley KE. New drugs for the treatment oftuberculosis. Clin Chest Med 2019; 40 (4): 811-827. DOI:10.1016/j.ccm.2019.08.001.

  31. Kim JH, Kwon OJ, Kim YS, Park MS, Hwang S, Shim TS.Bedaquiline in multidrug-resistant tuberculosis treatment:Safety and efficacy in a Korean subpopulation. Respir Investig2020; 51 (8): 45-51. DOI: 10.1016/j.resinv.2019.08.004.

  32. Pontali E, Raviglione MC, Migliori G B. Regimens to treatmultidrug-resistant tuberculosis: past, present and futureperspectives. Eur Respir Rev 2019; 28 (152). 190035. DOI:10.1183/16000617.0035-2019.

  33. Fujiwara M, Kawasaki M, Hariguchi N, Liu Y, MatsumotoM. Mechanisms of resistance to delamanid, a drug forMycobacterium tuberculosis. Tuberculosis (Edinb) 2018;108: 186-194. DOI: 10.1016/j.tube.2017.12.006.

  34. von Groote-Bidlingmaier F, Patientia R, Sanchez E. Efficacyand safety of delamanid in combination with an optimisedbackground regimen for treatment of multidrug-resistant tuberculosis:a multicentre, randomised, double-blind, placebocontrolled,parallel group phase 3 trial. Lancet Respir Med2019; 7 (3): 249-259. doi: 10.1016/S2213-2600(18)30426-0.

  35. Agyeman AA, Ofori-Asenso R. Efficacy and safety profile oflinezolid in the treatment of multidrug-resistant (MDR) andextensively drug-resistant (XDR) tuberculosis: a systematicreview and meta-analysis. Ann Clin Microbiol Antimicrob2016; 15 (1): 41. DOI: 10.1186/s12941-016-0156-y.

  36. Cholo MC, Mothiba MT, Fourie B, Anderson R. Mechanismsof action and therapeutic efficacies of the lipophilicantimycobacterial agents clofazimine and bedaquiline.J Antimicrob Chemother 2017; 72 (2): 338-353. DOI:10.1093/jac/dkw426.

  37. Silva DR, Mello FCQ, Migliori GB. Shortened tuberculosistreatment regimens: what is new? J Bras Pneumol 2020; 46(02): e20200009. DOI: 10.36416/1806-3756/e20200009.

  38. Brouqui P, Quenard F, Drancourt M. Old antibiotics foremerging multidrug-resistant/extensively drug-resistanttuberculosis (MDR/XDR-TB). Int J Antimicrob Agents. 2017;49(5): 554-557. DOI: 10.1016/j.ijantimicag.2017.02.008.

  39. Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z,Dheda K. Drug-resistant tuberculosis: An update on diseaseburden, diagnosis and treatment. Respirology 2018; 23 (7):656-673. DOI: 10.1111/resp.13304.

  40. Khan U, Huerga H, Khan AJ, Mitnick C, et al. The endTBobservational study protocol: treatment of MDR-TB withbedaquiline or delamanid containing regimens. BMC InfectDis 2019; 19 (1): 733. DOI: 10.1186/s12879-019-4378-4.

  41. Tiberi S, Muñoz M, Duarte R, Dalcolmo M, D'AmbrosioL, Migliori GB. New drugs and perspectives for new antituberculosisregimens. Pulmonology 2018; 24 (2): 86-98.DOI: 10.1016/j.rppnen.2017.10.009.

  42. Gardner CA, Acharya T, Pablos-Méndez A. The global alliancefor tuberculosis drug development—accomplishmentsand future directions. Clin Chest Med 2005; 26 (2): 341-347.doi: 10.1016/j.ccm.2005.02.008.

  43. Organización Mundial de la Salud. Anti-tuberculosis drugresistance in the world (No. WHO/CDS/TB/2000.278).2000, World Health Organization.

  44. Frontières MS. Revised international definitions in tuberculosiscontrol: comments from the Aral Sea Area tuberculosisprogramme. Int J Tuberc Lung Dis 2001; 5 (11): 1071-1076.

  45. Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, et al.World Health Organization recommendations on thetreatment of drug-resistant tuberculosis, 2020 update.Eur Respir J 2021; 57 (6). doi: 10.1183/13993003.03300-2020.

  46. Loveday M, Reuter A, Furin J, Seddon JA, Cox H. TheSTREAM trial: missed opportunities and lessons for futureclinical trials. Lancet Infect Dis 2019; 19 (4): 351-353. DOI:10.1016/S1473-3099(19)30106-9.

  47. Pontali E, Sotgiu G, Tiberi S, Tadolini M, et al. Combinedtreatment of drug-resistant tuberculosis with bedaquilineand delamanid: a systematic review. Eur Respir J. 2018; 52(1): 1800934. DOI: 10.1183/13993003.00934-2018.

  48. Conradie F, Diacon AH, Ngubane N, Howell P, et al.Treatment of highly drug-resistant pulmonary tuberculosis.N Engl J Med 2020; 382 (10): 893-902. DOI: 10.1056/NEJMoa1901814.

  49. Mok J, Kang H, Koh WJ, Woo B, et al. Final treatmentoutcomes of delamanid-containing regimens in patientswith MDR-/XDR-TB in South Korea. Eur Respir J 2019; 54(5): 1900811. DOI: 10.1183/13993003.00811-2019.

  50. Caminero JA, García-García JM, Caylà JA, García-Pérez FJ,Palacios JJ, Ruiz-Manzano J. Update of SEPAR guideline“Diagnosis and Treatment of Drug-Resistant Tuberculosis”.Arch Bronconeumol 2020; 56 (8): 514-521. DOI: 10.1016/j.arbres.2020.03.021




2020     |     www.medigraphic.com